Pipeline

Business model

01 Pipeline
02 Partnership

In addition to its own research and development, C4U is also conducting research and development of new treatments for diseases for which there is still no fundamental cure using CRISPR-Cas3 technology through joint research and licensing with pharmaceutical companies, biotech companies, and medical and research institutions.

Therapeutic Area
Partner
Status
Detailss

In-House Pipeline

- Mucolipidosis II/III
- Collaborative research
- Press Release
  - 2021.08.12 C4U and National Center for Child Health and Development Started Joint Research
- Undisclosed
- Discovery phase

Partnered Pipeline

- Solid tumors (Allogeneic CAR-T)
- Noile-Immune Biotech
- Collaborative research・License
- Press Release
  - 2020.5.25 C4U and Noile-Immune Biotech Partnership on PRIME Allogeneic CAR-T Cell Therapy Using CRISPR/Cas3 Genome Editing Technology
- CNS
- Sumitomo Pharma
- License
- Press Release
- Undisclosed
- Sumitomo Pharma
- Collaborative research
- Press Release
  - 2022.08.31 C4U and Sumitomo Dainippon Pharma enter into Collaborative Research and Alliance Agreement
- Undisclosed
- Undisclosed
- Collaborative research
- Undisclosed
- Undisclosed
- Collaborative research
- Epidermolysis Bullosa
- Healiva
- Collaborative research
- Press Release
  - 2023.10.30 C4U and Healiva enter into Strategic Alliance Agreement
- Undisclosed
- Cyto-Facto
- Collaborative research
- Press Release
  - 2024.08.05 C4U and Cyto-Facto enter into Collaborative Research Agreement
- Undisclosed
- iXgene
- Collaborative research
- Press Release
  - 2024.12.25 C4U and iXgene execute a collaborative research agreement